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ABSTRACT 
The cytokines interleukin-1 (IL-l) and IL-6 are thought to be 
important mediators in the suppression of thyroid function during 
nonthyroidal illness. In this study we compared the effects of IL-1 and 
IL-6 intiion on the hypothalamus-pituitary-thyroid axis in rats. Cy- 
tokines were administered by continuous ip infusion of 4 pg IL-la/day 
for 1, 2, or 7 days or of 15 rg IL-G/day for 7 days. Body weight and 
temperature, food and water intake, and plasma TSH, T,, free T, (FT,), 
Tat and corticosterone levels were measured daily, and hypothalamic 
pro-TRH messenger RNA (mRNA) and hypophyaial TSH/3 mRNA 
were determined after termination of the experiments. Compared with 
saline-treated controls, infusion of IL-l, but not of IL-6, produced a 
transient decrease in food and water intake, a transient increase in 
body temperature, and a prolonged decrease in body weight. Both 
cvtokines caused transient decreases in plasma TSH and T,, which 
were greater and more prolonged with Ii-1 than with IL-6, whereas 
they effected similar transient increases in the plasma FT, fraction. 
Infusion with IL-l, but not IL-6, also induced transient decreases in 
plasma FT, and Ts and a transient increase in plasma corticosterone. 
Hypothalamic pro-TRH mRNA was significantly decreased (-73%) 
after 7 days, but not after 1 or 2 days, of IL-l infusion and was 
unaffected by IL-6 infusion. Hypophysial TSHfl mRNA was signifi- 
cantly decreased after 2 (-62%) and 7 (-62%) days, but not after 1 
day, of IL-l infusion and was unaffected by IL-6 infusion. These results 
are in agreement with previous findings that IL-l, more so than IL-6, 
directly inhibits thyroid hormone production. They also indicate that 
IL-l and IL-6 both decrease plasma T, binding. Furthermore, both 
cytokines induce an acute and dramatic decrease in plasma TSH before 
(IL-l) or even without (IL-6) a decrease in hypothalamic pro-TRH 
mRNA or hypophysial TSHfi mRNA, suggesting that the acute de- 
crease in TSH secretion is not caused by decreased pro-TRH and 
TSHj3 gene expression. The TSH-suppressive effect of IL-6, either 
administered as such or induced by IL-1 infusion, may be due to a 
direct effect on the thyrotroph, whereas additional effects of IL-1 may 
involve changes in the hypothalamic release of somatostatin or TRH. 
As glucucorticoids are known to suppress hypothalamic TRH mRNA 
levels, it is speculated that the decrease in pro-TRH gene expression 
caused by prolonged infusion of IL-l is mediated by the high plasma 
corticosterone levels. (Endocrinology 135: 1336-1345,1994) 
D URING acute and chronic systemic illness, profound changes in thyroid function occur in both humans 
(l-3) and animals (4). In humans, the most characteristic 
changes are a decrease in the plasma TS level and an increase 
in the plasma level of rT3. Plasma T4 may also be decreased 
in severely ill patients (3), mainly due to reduced binding to 
transport proteins (5, 6), as plasma free T, (FT4) usually 
remains within the normal range. It has been suggested that 
cytokines are important mediators of the changes in thyroid 
economy during diseases in which the immune system is 
activated (4, 7-11). Cytokines are polypeptides primarily 
produced by activated monocytes and macrophages, which 
play important roles not only in regulating the immune 
system, but also in interacting with several endocrine systems 
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(12-17). In rats, a single injection of interleukin-1 (IL-l) 
lowered plasma TSH and thyroid hormone levels within 5 h 
(4). Continuous infusion of IL-l@ induced in the rat decreases 
in plasma TSH, FT*, and T4 binding (18). It is, however, not 
fully understood how cytokines suppress the pituitary-thy- 
roid function. 
Inflammation stimulates the production of a cascade of 
cytokines, of which, in particular, tumor necrosis factor-a, 
IL-l, and IL-6 represent key factors for communication be- 
tween the immune and neuroendocrine systems (19-21). As 
part of the pleiotropic effects of IL-1 is mediated by IL-6, we 
compared the effects of short and long term infusion of IL-l 
and long-term infusion of IL-6 on the hypothalamic-pitui- 
tary-thyroid axis. To identify the sites of action of IL-l and 
IL-6, their effects were measured on plasma T4, FT4, TB, TSH, 
and corticosterone; TRH content in median eminence; hy- 
pothalamic levels of pro-TRH messenger RNA (mRNA); and 
pituitary levels of TSHP mRNA. As hepatic type I deiodinase 
is responsible for 60-70s of peripheral T3 production in 
euthyroid rats (22), we also measured the activity of this 
enzyme during IL infusion. 
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Materials and Methods 
Materials 
Recombinant human IL-la (IL-l) was kindly provided by Dr. P. 
Lomedico (Hoffman LaRoche, Nutley, NJ). The preparation, supplied in 
50 mu potassium phosphate (pH 6.5) and 0.1 M sodium chloride, had 
an activitv of 2 X 10’ U/ml (DlO assay) and a specific activity of 3 X 
10s U/mg protein. According to the -specifications of the suppliers, 
endotoxin contamination was neelidble (0.5 U/ml IL-1 solution, as 
detected in the limulus amoebocytz &ate assay).’ 
Human IL-6, produced by recombinant DNA technology in Esche- 
rich coli, was obtained from Sandoz (Sandoz Forschungsinstitut, 
Vienna, Austria). The specific activity of the preparation was 52 X 
lo6 U/mg (by B13.29 assay). The preparation (SDZ 280-969, batch 
PPG9001) was supplied in 20 mu sodium phosphate (pH 6.7), and 
endotoxin contamination was negligible (CO.4 U/mg protein). 
Both IL-1 and IL-6 were diluted in sterile pyrogen-free saline [0.9% 
NaCl (wt/vol) in water]. All chemicals used were of analytical grade. 
The concentrations of IL-1 and IL-6 used for infusion in this study were 
based upon the findings of a previous study performed by Hermus ef 
al. (18) and a pilot study in which three concentrations of IL-6 infusion 
were studied in rats (data not shown). 
Animals 
Male albino Wistar rats (Cpb:WU) were obtained from the local 
breeding facility and individually housed in Plexiglass cages in an 
artificially lighted room (lights on at 0700 h; lights off at 1900 h). Rats 
were provided with commercial rat chow containing 22% protein, 4.8% 
fat, and 66.8% carbohydrates (RMH-TH, Hope Farms, Woerden, The 
Netherlands) and tap water ad libifum. At the time of the start of the 
experiments, rats were 10 weeks old and weighed 200-220 g. Animal 
procedures were approved by the institutional review board. 
Experimental design 
Long term infusion. To diminish the stress of the experimental procedure, 
rats were handled daily, starting at least 1 week before the insertion of 
an indwelling cannula-into an external jugular vein. Rats were cannu- 
lated accordine to the method described bv Steffens (23) with some 
minor modifi&ons (24). After insertion, the cannula was ‘filled with a 
0.9% NaCl solution containing heparin (500 IU/ml; Organon Teknika, 
Boxtel, The Netherlands) and polyvinylpyrrolidone (1 g/ml; Merck, 
Darmstadt, Germany). 
Seven to 9 days after cannulation, rats were implanted with an Alzet 
osmotic minipump (model 2001, Alzet Corp., Palo Alto, CA; 1 pi/h for 
7 davs). Rats were infused for 7 days with IL-1 (4 &day) or IL-6 (15 
rg/day) dissolved in sterile pyrogen-free physioiogiGa1 saline or with 
saline alone. The pumps were equilibrated by immersion in physiological 
saline solution for 3-4 h at 37 C according to the instructions of the 
manufacturer and then implanted ip in ether-anesthetized animals be- 
tween 1400-1600 h (dav 0). The indwelline. cannula and the osmotic 
pump were tolerated wei by the rats with no%bvious signs of discomfort 
or infection. 
From the freely moving rats, blood samples of 2 ml were withdrawn 
from the jugular venous cannula on several days of the experiment 
starting 2 days before implantation of the osmotic minipumps (18). 
Because of the circadian rhythm in hormone release, blood was sampled 
at about the same time each day (between 1000-1200 h). Blood samples 
were collected in prechilled tubes containing 60 ~1 10% (wt/vol) EDTA 
in saline, gently shaken, and centrifuged for 10 min at 1500 X g at 4 C. 
After removal of the plasma, the residue containing red blood cells was 
resuspended in sterile physiological saline solution (1.5 ml) and returned 
through the jugular venous cannula to each rat. Plasma samples were 
aliquoted and stored at -20 C until assayed. 
In all rats, body weight was measured daily between 0815-0900 h. 
Body temperature was measured daily between 0815-0900 h and be- 
tween 1300-1430 h in conscious hand-held rats by insertion of a thermal 
probe into the rectum. The probe was connected to a digital temperature 
monitor (Digital DTlOO, Elbatron, Kerkdriel, The Netherlands). Mean 
daily temperature for each rat was determined by averaging the morning 
and afternoon rectal temperatures. The daily food and water intake was 
estimated by weighing the residual food pellets and water for individual 
cages. 
At the end of the experiment (day 7), the rats were killed by decapi- 
tation. The livers were cut into pieces, frozen in liquid nitrogen, and 
kept at -80 C until the estimation of type I deiodinase activity. The 
skull was opened, and the brain was removed. The hypothalamus was 
isolated (limits, posterior border of the chiasmatic opticum, anterior 
border of the mamillary bodies, and lateral hypothalamic border; height, 
-3 mm) for the determination of pro-TRH mRNA. Also, the pituitary 
gland was isolated to estimate the level of TSHB mRNA. Both tissues 
were snap-frozen in liquid nitrogen and kept at -80 C until determi- 
nation of pro-TRH and TSHfl mRNAs. 
Short term infusion. Rats were infused with IL-1 (4 &day) for 1 day 
(osmotic minipump model 2001D; 8 @l/h for 1 day) or 2 days (osmotic 
minipump model 1003D; 1 pi/h for 3 days) or with saline. The pumps 
were implanted between 1400-1600 h. These animals had not been 
implanted with a cannula into the jugular vein. After 1 or 2 days of 
infusion, trunk blood was collected after decapitation of the rats between 
1200-1500 h. The livers, hypothalami, and pituitaries were collected 
according to the methods described above. From animals infused for 1 
day with IL-1 or saline, the median eminence was also collected. This 
was performed by grasping the hypophysial stalk with forceps and 
lifting it from the brain. The protruding tissue fragment, comprising the 
hypophysial stalk and the median eminence, but referred to as median 
eminence, was cut from the brain and placed in 2 ml methanol to 
determine the TRH content. 
Deiodinase assay 
Livers were homogenized, and type I deiodinase activity was deter- 
mined in the homogenate by analysis of the production of radioiodide 
from outer ring-labeled rTg (25). Type I deiodinase activity was measured 
in incubations of 1 PM [‘251]rT3 for 20 min at 37 C with 50 rg/ml 
homogenate protein in 0.1 M phosphate buffer (pH 7.2), 2 mu EDTA, 
and 5 mu dithiothreitol by the method described by Fekkes et al. (26). 
Hormone assays 
Levels of TSH were measured by RIA using materials and protocols 
supplied by the NIDDK, with TSH RP-2 as standard. The RIA for TRH 
was performed with antiserum 4319 (final dilution, l:lO,OOO), as re- 
ported previously (27). Plasma T3 and T4 were estimated by specific 
RIAs in unextracted plasma, as described by Hermus et al. (18). The 
plasma FTI fraction was determined by means of the SPAC FTr assay 
kit (Byk-Sangtec Diagnostica, Dietzenbach, Germany) (28), and the 
plasma FT, concentration was calculated as the product of the total T1 
level and the FTI fraction. Plasma corticosterone was measured by RIA, 
as described by Sweep et al. (24). Intra- and interassay coefficients of 
variation for the assays varied between 3-17%. 
Pro-TRH mRNA determination 
Pro-TRH mRNA was measured by a ribonuclease (RNase) protection 
assay, using a labeled antisense complementary RNA (cRNA) probe. 
Total hypothalamic RNA was isolated by acid guanidinium thiocyanate- 
phenol-chloroform extraction (29). From each sample, 10 pg hypothal- 
amic RNA were used in a RNase protection assay, as described previ- 
ously by Sambrook et al. (30) with a few modifications. Hybridization 
was carried out overnight at 55 C; for the RNase digestion, 2 U/ml 
RNase-Tl and 0.2 &ml RNase-A (both from Boehringer, Mannheim, 
Germany) were used. The 1322-basepair (bp) EcoRI/PitI rat pro-TRH 
complementary DNA (cDNA) insert in a pSP65 vector (31) was kindly 
provided by Dr. S. L. Lee (New England Medical Center Hospitals, 
Boston, MA). The cRNA probe was synthesized using fragment 981- 
1322 of rat pro-TRH cDNA as a template. This 351-bp RsaI fragment 
was isolated after agarose gel electrophoresis. Variations in procedure 
were accounted for by normalizing to the glyceraldehyde-3-phosphate 
dehydrogenase gene (GAPDH) expression in each sample, using a cRNA 
probe transcribed from a 410-bp PstI/SauAl fragment of the cDNA 
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inserted in pBlueScript KS(-) (Stratagene, La Jolla, CA). Under the diges- 
tion conditions used, the GAPDH signal consisted of 2 bands of about 
310 and 320 nucleotides (Fig. 1). Autoradiographs were scanned densi- 
tometrically with a LKB 2222-020 UltraScan XL Laser Densitometer 
(Pharmacia LKB Biotechnology 1987, Bromma, Sweden). The peak areas, 
corresponding to the bands, were integrated by the computer. Results 
were calculated as the ratio between the integrated optical densities of 
pro-TRH and GAPDH mRNA, and expressed as a percentage of the 
mean of the respective control values. 
Pituitary TSH/3 mRNA measurement 
Total pituitary RNA was isolated by acid guanidinium thiocyanate- 
phenol-chloroform extraction (29), and 20 ag RNA were subjected to 
denaturing agarose gel electrophoresis and blotted onto Hybond N+ 
filter (Amersham International PLC, Aylesbury, United Kingdom). TSH/3 
cDNA (420 bp), inserted in the PstI site of a pBR322 vector, was kindly 
provided by Dr. W. W. Chin (Brigham and Women’s Hospital, Bos- 
ton, MA) (32). After electroporation in DH5 cells, DNA was isolated and 
digested with PM. The DNA fragment was isolated after agarose gel 
electrophoresis. Northern blotting and random primed labeling of the 
TSH@ cDNA with [32P]deoxy-ATP were performed according to the 
method of Sambrook et al. (30). Variations in loading were accounted 
for by normalizing to the B-a&n mRNA content in each lane, which 
was measured by hybridization with a 32P-labeled rat actin cDNA probe 
(Fig. 1). AutoradoGaphs were quantified densitometically with a model 
620 video densitometer using 2D Analvst II software (Bio-Rad, Rich- 
mond, CA). Results were cal&lated as &e ratios between the integrated 
optical densities of TSl@ mRNA and &actin mRNA, and expressed as 
a percentage of the mean of the respective control values. 
Statistical analysis 
Results are presented as the mean f  SM. A nonparametic test 
(Wilcoxon matched pairs, signed ranks test) and analysis of variance for 
a repeated measures design were used to analyze the data. Provided 
that significant overall effects were obtained by analysis of variance, 
further comparisons between groups were made using Duncan’s multi- 
ple range test. Differences were considered significant at P < 0.05. 
Results 
Infusion of IL-l (4 &day) induced signs of physical 
discomfort in the animals, including piloerection and de- 
TSHs ProTRH 
actin - 
ProTRH - 
, GAPDH [ 
c IL C IL 
FIG. 1. Effect of continuous infusion of saline (C) or 4 pg IL-l/day 
(IL) for 1 week on pituitary TSHfi mRNA (.&panel) and hypothalamic 
pro-TRH mRNA (right panel). Northern blot hybridization analysis 
was used to estimate TSH@ mRNA, whereas pro-TRH mRNA was 
determined with a RNase protection assay. Variation in loading was 
accounted for by normalizing to the &actin mRNA and GAPDH 
mRNA contents, respectively. 
creased physical activity, as observed on the first day after 
implantation of the pumps. This visually observable uneasi- 
ness gradually diminished and disappeared on day 2. Infu- 
sion of IL-6 at a dose of 15 &day did not induce signs of 
discomfort. Treatment of rats with saline did not perceptibly 
distress the animals. 
Effects of IL-l and IL-6 on rectal temperature and body weight 
Saline-treated rats maintained a virtually constant mean 
daily rectal temperature throughout the experimental period. 
On the first day of infusion, IL-1 induced a significant 
increase in rectal temperature, which returned to normal 
levels between days 2-4 (Fig. 2), whereas IL-6-treated rats 
had no significant increase in rectal temperature compared 
to saline-treated rats. 
There was a small decrease in body weight on the first 
day of saline infusion (Fig. 2). A similar weight loss was 
found in animals treated with IL-6 (15 pg/day), whereas rats 
infused with IL-l (4 rg/day) showed a more distinct weight 
loss. The body weights of IL-l-treated rats reached minimal 
levels on the second day of infusion. Thereafter, the rate of 
body weight gain was slightly higher in IL-l-treated rats 
than in saline-treated control rats. 
Effects of IL-l and IL-6 on food and fluid intake 
The effects of chronic administration of IL-l and IL-6 on 
food and fluid consumption were monitored for 9 days, and 
results are shown in Fig. 3. There was a transient slight 
reduction in food consumption in saline-treated rats after 
implantation of the osmotic pumps. Compared to saline- 
treated animals, rats treated with IL-6 (15 &day) showed 
no significant change in food consumption, whereas the 
infusion of IL-l (4 rg/day) caused a significant decrease in 
food intake compared to that in saline-treated rats during 
the first 5 days after starting the infusion. Chronic infusion 
of physiological saline, IL-l, or IL-6 into rats caused a signif- 
icant decrease in total daily fluid intake on the first day of 
the infusion. During the following day, the fluid intake had 
returned to preinfusion values in all groups. 
Effects of IL-l on plasma T, FT, T3, TSH, and 
corticosterone bveki 
Figures 4 and 5 show the effects of continuous infusion 
for 1 week with 4 pg IL-l/day or saline on plasma T4, FT*, 
Ts, and TSH. Infusion of 4 pg IL-l/day induced a highly 
significant decrease in plasma T1, which reached minimum 
levels on day 2 and remained significantly suppressed 
throughout the experimental period. IL-l induced a marked 
transient increase in the plasma FT, fraction (not shown), 
and the decline in plasma FTI in IL-l rats was less pro- 
nounced and of shorter duration than that in total Ta. By the 
end of the infusion period, when plasma Tq levels were still 
decreased, plasma FTI had returned to control levels. Parallel 
with the decrease in Tq concentrations, plasma TJ was signif- 
icantly lower in IL-l-infused animals than in saline-treated 
rats. The nadir was reached on day 2 of the infusion, and 
plasma TJ remained significantly lower in IL-l-treated ani- 
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FIG. 2. Effects of continuous infusion of 4 pg IL-l/day (Cl), 15 rg IL-S/day (O), or saline (W) for 1 week on body weight and rectal temperature. 
Data are presented as the mean f  SEM of 7-17 rats. *, P < 0.05 compared to saline-infused rats. 
mals than in saline-treated animals until the end of the 
experiment. Chronic administration of IL-l induced a dra- 
matic decline in plasma TSH. The nadir was reached on the 
first day of the infusion, after which plasma TSH levels in 
IL-l-treated rats started to increase slowly. Short term infu- 
sion with IL-l had effects on thyroid function similar to those 
of long term infusion (Table 1). Levels of plasma corticoster- 
one increased dramatically after 1 day of IL-1 infusion and 
were significantly elevated compared to levels in control rats 
for at least 4 days (Fig. 6). 
Effects of IL-l on pro-TRH mRNA, TSHP mRNA, and 
type I deiodinase 
In Table 2, the effects of treatment with IL-l on hypothal- 
amic pro-TRH mRNA, pituitary TSH@ mRNA, and liver type 
I deiodinase are given. During the first 2 days of infusion, 
the levels of hypothalamic pro-TRH mRNA in IL-l-treated 
rats were not significantly different from those in saline- 
treated rats. In addition, the TRH content in the median 
eminence did not change after 1 day of IL-l’infusion (Table 
2). However, on day 7 of infusion, the level of hypothalamic 
pro-TRH mRNA was 73% lower in IL-1 rats than in controls. 
In the pituitary gland, the levels of TSH/3 mRNA showed a 
significant decline after 2 days of IL-l infusion. On days 2 
and 7 of infusion, pituitary TSH/3 mRNA levels were reduced 
to 38% of the levels in control rats. Liver type I deiodinase 
activity showed a significant decline due to IL-l infusion on 
days 1,2, and 7. 
Effects of IL-6 on phna T4, FT,, T3, TSH, and corticosterone 
Figures 4 and 5 show the effects of continuous infusion of 
rats for 1 week with IL-6 (15 pg/day) or saline on plasma Tq, 
FT4, TJ, and TSH. Plasma T, was significantly lower in IL-6- 
infused animals than in control rats on days 2 and 3 of 
infusion. IL-6 produced a marked transient increase in the 
plasma FT4 fraction (not shown), but plasma FT, in IL-6 rats 
did not change during the experiment. A significant decrease 
in plasma T3 was found in IL-6-treated rats compared to 
their starting levels, but no significant effects were observed 
compared to saline-infused control values. Infusion of IL-6 
induced a significant decline in plasma TSH. The nadir was 
reached on day 2 of the infusion, but plasma TSH recovered 
quickly, and within 4 days, the levels were again in the range 
found in control animals. Compared to the effects of IL-l 
infusion on thyroid and pituitary function, the effects of IL- 
6 administration were less pronounced. This was also seen 
in the effects of these ILs on plasma corticosterone, because 
IL-6 administration did not affect the levels of plasma corti- 
costerone, whereas IL-l did (Fig. 6). 
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FIG. 3. Effects of continuous infusion of 4 rg IL-l/day (O), 15 pg IL-G/day (0), or saline (D) for 1 week on food and water intake. Data are 
presented as the mean f  SEM of 7-17 rats. *, P < 0.05 compared to saline-infused rata. 
Effects of IL-6 on pro-TRH mRNA and TSH mRNA 
In Table 3, the effects of continuous treatment with IL-6 
on hypothalamic pro-TRH mRNA and pituitary TSHP 
mRNA are shown. After 7 days of IL-6 administration, no 
effects were seen on the levels of hypothalamic pro-TRH 
mRNA. In the pituitary gland, the levels of TSH/3 mRNA 
showed an insignificant decline after 7 days of infusion of 
IL-6. 
Discussion 
The suppressive effects of short term and continuous in 
viva IL-l administration on pituitary-thyroid function in rats 
have been reported in two previous studies (4, 18), in which 
it was shown that the reduction of food intake cannot explain 
the changes in thyroid hormone and TSH levels during IL-l 
treatment (18). As the mechanisms of the effects of cytokine 
on thyroid function are not fully understood, we studied in 
particular the centrally mediated effects of IL-la! in more 
detail. Furthermore, as a number of IL-l effects may be 
mediated by IL-6, we compared the effects of IL-l and IL-6 
infusions on plasma T4, FT4, T3, TSH, and corticosterone; 
hypophysial TSHP mRNA; median eminence content of 
TRH; and hypothalamic pro-TRH mRNA. 
Infusion of both IL-l and IL-6 produced a marked tran- 
sient decrease in plasma T1, which was more pronounced 
with IL-l than with IL-6. Plasma FT, was also decreased by 
IL-l, but not by IL-6. These cytokines produced similar 
increases in the plasma FT( fraction (not shown), suggesting 
that IL-1 and IL-6 infusions both decreased plasma T4 bind- 
ing. Previous findings have shown that the decrease in 
plasma T, binding during IL-l administration is due at least 
in part to a decrease in the plasma level of transthyretin, 
which is the principal plasma T,-binding protein in rats (18). 
A decrease in transthyretin production is one of the hallmarks 
of the acute phase response of the liver to inflammation, 
which is largely mediated by IL-6 (33). As IL-l is known to 
stimulate IL-6 production (33), it is likely that the effect of 
IL-l on plasma T4 binding is mediated by IL-6. However, 
besides the fall in plasma transthyretin a decrease in plasma 
albumin (33) and an increase in plasma FFA (4) may contrib- 
ute to the lowered plasma T4 binding during IL-l and IL-6 
administration. 
The decrease in plasma FT4 during IL-1 administration 
may be the result of a decrease in thyroidal T, production 
and/or an increase in plasma T4 clearance. Dubuis et al. (4) 
demonstrated that plasma T4 clearance is not affected by IL- 
1 administration despite .a large increase in the plasma FT, 
fraction, suggesting that the metabolism of T4 in the tissues 
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FIG. 4. Effects of continuous infusion of 4 pg IL-l/day (O), 15 pg IL-S/day (O), or saline (m) for 1 week on plasma TSH and Ts levels. Blood 
samples were taken from an indwelling jugular venous cannula between 10-12 h. Data are presented as the mean f  SEM of ‘7-17 rats. *, P < 0.05 
compared to saline-infused rats. 
is decreased. This could be due to a decrease in tissue 
availability of plasma FT4 or a decrease in the activity of Tq 
metabolic pathways. Evidence has been presented that the 
fractional transfer rate constant for T4 transport from plasma 
to liver is decreased in humans during severe illness and 
fasting (34, 35). Although changes in hepatic type I deio- 
dinase activity have not been detected previously after both 
short and long term administration of IL-l to rats (4, 18), 
significantly decreased deiodinase activities were found in 
the present study after 1, 2, and 7 days of IL-1 infusion. The 
reason for the differences in the effects of IL-l on liver type 
I deiodinase between the previous (18) and the present 
studies could be due to the higher dose of IL-l infused in 
the present study (4 VS. 2 rg/day). It should be stressed, 
however, that the decreases we observed were relatively 
small (-25%). It is not known to what extent these decreases 
were caused directly by an effect of IL-l or IL-6 on the liver 
or indirectly through the IL-l-induced reduced food intake 
or hypothyroid state, which are both associated with a de- 
crease in hepatic deiodinase activity (36). Surprisingly, infu- 
sion of mice with IL-l for 3 days has been found to increase 
hepatic type I deiodinase activity, in contrast to the decrease 
found in animals with a similar reduction in food intake (7). 
The reduced plasma T4 and FTI levels induced by IL-l in 
combination with a presumably normal plasma Tq clearance 
rate, as found by others (4), suggest that IL-l inhibits thy- 
roidal T4 secretion. The decrease in plasma Ts during IL-l 
administration may be due to 1) diminished TJ secretion, 2) 
reduced peripheral T3 production through a decrease in type 
I deiodinase activity and/or Tq substrate availability, and/or 
3) decreased plasma T3 binding. An increased plasma FT3 
fraction was observed by Dubuis et al. (4) after IL-l admin- 
istration, although the effect was smaller than the increase 
in the plasma FT4 fraction. IL-l can inhibit thyroidal T* and 
TS secretion by a well documented direct effect on the 
thyrocyte, whereas IL-6 has little or no direct effect on 
thyroid activity (8, 37-40). However, the effects of IL-1 on 
thyroid function also appear to be mediated at least in part 
by the decrease in serum TSH. 
In agreement with previous reports, IL-l infusion resulted 
in a dramatic and acute decrease in serum TSH (4,18), which 
was more rapid in onset and longer in duration than the 
decrease induced by IL-6. The latter may explain in part 
why, in contrast with IL-l, the decrease in serum TSH in IL- 
B-treated rats is not associated with a decrease in serum FT,. 
Although the effects of cytokine administration on the clear- 
ance of plasma TSH have not been determined, the decreased 
serum TSH level probably reflects an acute decrease in 
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FIG. 5. Effects of continuous infusion of 4 fig IL-l/day (Cl), 15 pg IL-G/day (O), or saline (B) for 1 week on plasma T, and FT, levels. Blood 
samples were taken daily from an indwelling jugular venous cannula between lo-12 h. Data are presented as the mean + SEM of 7-17 rats. *, P < 
O.O%compared to saline-infused rats. 
TABLE 1. The effects of continuous infusion of IL-1 (4 pg/day) or 
saline for 1 or 2 days were measured on plasma TSH, T3, and T1 
levels in male rats 
Parameter Treatment Day 1 Day 2 
TSH (rig/ml) Saline 0.38 f 0.08 0.81 -c 0.09 
IL-1 0.11 + 0.02” 0.06 zk 0.03" 
Ta (nmol/liter) Saline 0.70 + 0.06 0.61 f 0.03 
IL-l 0.25 k 0.02" 0.20 + 0.02" 
T, (nmol/liter) Saline 40.7 f 3.5 33.7 3z 1.4 
IL-l 12.3 f 1.3” 4.5 + 0.8" 
Data are presented as the mean & SEM of six or seven rats. After 1 
or 2 days of infusion, trunk blood was collected after decapitation. 
a P < 0.05 compared to saline-infused rats. 
hypophyseal TSH secretion. This may be due to the direct 
effects of IL-1 and IL-6 on the thyrotroph or to alterations 
in hypothalamic or peripheral factors involved with TSH 
regulation. Concerning the latter, plasma FT4 may be tran- 
siently increased acutely after commencement of cytokine 
administration, resulting in long-lived feedback inhibition of 
TSH secretion (4). It is remarkable, however, that hypo- 
physeal TSH/3 mRNA was not decreased after 1 day of IL-l 
administration at the time serum TSH was at its nadir. 
Although this lack of an acute effect on hypophyseal TSHP 
mRNA does not exclude a decrease in TSH synthesis, these 
results suggest that the IL-l-induced decrease in serum TSH 
after 1 day of IL-l infusion is not secondary to a decreased 
TSH biosynthesis. 
Inflammation in general and administration of cytokines 
such as IL-1 in particular have profound effects on multiple 
hypophyseal hormones, e.g. ACTH secretion is acutely in- 
creased (12-16, 24), whereas the secretions of TSH (4, 18), 
LH (17), and GH (41) are decreased. The effects of IL-l on 
ACTH and LH secretion appear to be mediated largely by 
an increase in the hypothalamic production and secretion of 
CRF (4244) and a decrease in the production and secretion 
of GnRH (45, 46), respectively. Evidence has also been 
presented that inhibition of GH secretion by IL-1 is due to 
an increased supply of hypothalamic somatostatin (47, 48). 
A suprahypophysial action of IL-l on TSH secretion is sup- 
ported by observations that intracerebroventricular admin- 
istration of minute amounts of IL-1 produces a significant 
decline in plasma TSH in rats (49). The observation that not 
only basal serum TSH levels, but also their response to TRH 
stimulation are decreased during IL-1 infusion (18) suggests 
that a possible suprahypophysial effect of IL-l on TSH 
secretion may be mediated by increased hypothalamic release 
of somatostatin, rather than decreased release of TRH. This 
is in agreement with the present findings that serum TSH 
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TABLE 2. Effects of IL-l (4 ag/day) infusion for 1, 2, or 7 days on 
the levels of hypothalamic pro-TRH mRNA, median eminence (ME) 
content of TRH, hypophysial TSH/3 mRNA, and hepatic type I 
deiodinase in male rats 
Parameter Treatment Day 1 Day 2 Day 7 
Pro-TRH mRNA Saline 100+33 100 f. 25 100 * 27 
IL-1 135 f  17 125 + 56 27 + 7” 
TRH in ME (ng) Saline 1.3 & 0.25 
IL-l 1.4 f  0.28 % ii: 
TSHB mRNA Saline 100 + 33 100 + 14 100 f  10 
IL-l 76 f 30 38 f 8” 38 + 2” 
Deiodinase (pmol/ Saline 306 + 25 208 + 20 195 It 13 
min. mg) IL-l 243 f 9 159 + 8 123 f  13” 
Results are presented as the mean + SEM ratios of the optical 
densities of pro-TRH mRNA over GAPDH mRNA or of TSH@ mRNA 
over @-actin mRNA, and expressed as a percentage of the mean of the 
respective control values. Groups contained five to nine rats. ND, Not 
determined. 
’ P c 0.05 compared to saline-infused rats. 
TABLE 3. Effects of IL-6 (15 pg/day) infusion for 7 days on the 
levels of hypothalamic pro-TRH mRNA and hypophysial TSH@ 
mRNA in male rats 
Parameter Treatment Day I 
Pro-TRH mRNA Saline 100+9 
IL-6 103 f  22 
TSHfi mRNA Saline 100+31 
IL-6 64 + 7 
Results are presented as the mean + SEM ratios of the optical 
densities of pro-TRH mRNA over GAPDH mRNA or of TSHfl mRNA 
over @actin mRNA, and expressed as a percentage of the mean of the 
respective control values. Groups contained six to eight rats. 
and hypophyseal TSH/3 mRNA are decreased before an effect 
of IL-l is observed on hypothalamic pro-TRH mRNA. How- 
ever, the lack of short term effects of IL-l infusion on 
hypothalamic pro-TRH mRNA levels and median eminence 
TRH content does not exclude the possibility that IL-l acutely 
inhibits TRH release into hypophyseal portal blood. 
Direct effects of cytokines on anterior pituitary cells in 
culture have been reported, although this includes, paradox- 
ically, stimulation of the secretion of TSH, LH, and GH (14). 
In this respect it is worthwhile to mention that both IL-l and 
IL-6 are produced in the anterior pituitary and may, thus, 
act as paracrine factors in the regulation of hypophysial 
hormones (50, 51). In our study, IL-6 did not appear to act 
on the hypothalamus, as it failed to induce fever, nor did it 
stimulate the hypothalamic-hypophyseal-adrenal axis. It 
seems likely, therefore, that the effect of IL-6 on TSH secre- 
tion does not involve an action at the hypothalamic level, 
but, rather, a direct effect on the thyrotroph. As IL-l induces 
the production of IL-6 (33), the effect of IL-l infusion on 
TSH secretion may be mediated in part by this action of IL- 
6 on the pituitary. 
As pro-TRH gene expression is only suppressed after 7 
days of IL-l infusion, it is likely that this effect is mediated 
by factors other than IL-l itself. As discussed above, hy- 
pothalamic CRF gene expression is acutely stimulated by IL- 
1. As CRF neurons lie adjacent to TRH neurons in the 
paraventricular nucleus (PVN) (52, 53), the effects of IL-l 
on TRH neurons may be mediated by local factors produced 
by CRF neurons. Kakucska et al. (54) showed by in situ 
hybridization a reduction of pro-TRH mRNA in the PVN 24 
h after a constant intracerebroventricular infusion of IL-l, at 
the same time when pro-CRF mRNA in the PVN was in- 
creased. This inverse relationship between the levels of pro- 
TRH mRNA and CRF mRNA in PVN neurons has also been 
observed during hypothyroidism (55). Furthermore, high 
concentrations of glucocorticoids due to activation of the 
pituitary-adrenal axis may influence hypothalamic TRH pro- 
duction and secretion. In our study we demonstrated an 
increase in plasma corticosterone during at least 4 days of 
IL-l infusion, whereas IL-6 infusion had no effect. A sup- 
pressive effect of plasma corticosterone on TRH gene expres- 
sion would explain the different effects of IL-l and IL-6 on 
pro-TRH mRNA. This hypothesis is supported by 1) the 
 at Medical Library Erasmus MC on December 19, 2006 endo.endojournals.orgDownloaded from 
CHRONIC IL INFUSION AND THYROID FUNCTION Endo. 1994 
Voll35. No 4 
Pang XP, Hershman JM, Mire11 CJ, Pekary AE 1989 Impairment 
of hypothalamic-pituitary-thyroid function in rats treated with hu- 
man recombinant tumor necrosis factor-d (cachetin). Endocrinology 
125:76-84 
Ozawa M, Sato K, Han DC, Kawamaki M, Tsushima T, Shizume 
K 1988 Effects of tumor necrosis factor-cu/cachetin on thyroid hor- 
mone metabolism in mice. Endocrinology 123:1461-1467 
Woloski BM, Smith EM Meyer III WJ, Fuller GM, Blalock JE 
1985 Corticotropin-releasing activity of monokines. Science 230: 
1035-1037 
Besedovsky H, Del Rey A, Sorkin E, Dinarello CA 1986 Immu- 
noregulatory feedback between interleukin-1 and glucocorticoid 
hormones. Science 233:652-654 
Bernton EW, Beach JE, Holaway JW, Smallridge RC, Fein HG 
1987 Release of multiple hormones by a direct action of interleukin- 
1 on pituitary cells. Science 238:519-521 
Batemen A, Singh A, Kral T, Solomon S 1989 The immune- 
hypothalamic-pituitary-adrenal axis. Endocr Rev 10:92-112 
ddkahara S, -Goto F, Yoshinaga M 1989 lnterleukin 1 as an 
inflammatorv hormone. Acta Path01 lun 39:85-100 
Rivier C, Vale W 1990 Cytokines-act with the brain to inhibit 
luteinizing hormone secretion and ovulation in the rat. Endocrinol- 
ogy 127~849-856 
Hermus ARMM, Sweep CGJ, van der Meer MJM, Ross HA, Smals 
AGH, Benraad TJ, Kloppenborg PWC 1992 Continuous infusion 
of interleukin-10 induces a nonthyroidal illness syndrome in the rat. 
Endocrinology 131:2139-2146 
Shalably MR, Waage A, Aarden L, Espevik T 1989 Endotoxin, 
tumor necrosis factor-a! and interleukin 1 induce interleukin 6 
production in vim. Clin Immunol Immunopathol53:488-498 
Fang Y, Tracey KJ, Moldawer LL, Hesse DG, Manogue KB, 
Kennev IS. Lee AT. Kuo GC. Allison AC, Lowrv SF, Cerami A 
1989 &&bodies to cachectl&mor necrosis factor’reduce interleu- 
kin 10 and interleukin 6 appearance during lethal bacteremia. J Exp 
Med 170:1627-1633 
reduction in pro-TRH mRNA in the PVN after chronic high 
dose glucocorticoid treatment (56), 2) the presence of a 
consensus glucocorticoid response element in the TRH gene 
promoter (57), and 3) the coexistence of glucocorticoid recep- 
tors in TRH neurons in the PVN (58). 
In conclusion, our findings suggest that in addition to the 
direct inhibition of thyroid hormone production by IL-l, the 
multiple effects of this cytokine on the hypothalamus-pitui- 
tary-thyroid axis include 1) a decrease in plasma T4 binding; 
2) an acute decrease in TSH secretion, followed by a decrease 
in TSH synthesis; and 3) only after prolonged IL-l adminis- 
tration, a decrease in hypothalamic pro-TRH gene expres- 
sion. The transient decrease in plasma T4 binding and the 
acute decrease in TSH secretion are also observed during IL- 
6 infusion. The acute decrease in TSH secretion occurs before 
(IL-l) or even without (IL-6) a decrease in hypothalamic pro- 
TRH mRNA and, therefore, does not appear to be the result 
of decreased hypothalamic TRH synthesis, although a de- 
crease in hypothalamic TRH release is not excluded. The 
decreased TSH secretion may also involve an increased sup- 
ply of hypothalamic somatostatin as well as an effect via IL- 
6 directly on the thyrotroph. The decrease in pro-TRH gene 
expression by prolonged infusion of IL-1 may be mediated 
by the high plasma corticosterone levels. 
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